A detailed history of State Street Corp transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 492,005 shares of CADL stock, worth $4.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
492,005
Previous 472,798 4.06%
Holding current value
$4.9 Million
Previous $2.93 Million 16.31%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.02 - $7.76 $96,419 - $149,046
19,207 Added 4.06%
492,005 $3.41 Million
Q2 2024

Aug 14, 2024

BUY
$1.68 - $14.0 $747,932 - $6.23 Million
445,198 Added 1613.04%
472,798 $2.93 Million
Q1 2022

May 16, 2022

BUY
$3.66 - $8.0 $3,660 - $8,000
1,000 Added 3.76%
27,600 $140,000
Q3 2021

Nov 15, 2021

BUY
$5.75 - $11.21 $152,950 - $298,186
26,600 New
26,600 $288,000

Others Institutions Holding CADL

About Candel Therapeutics, Inc.


  • Ticker CADL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,891,900
  • Market Cap $288M
  • Description
  • Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...
More about CADL
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.